Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
301. |
ECCT/18/07/02 | CONRAD RING Phase IIa, 90-Day Safety, Adherence, and Acceptability Study of Intravaginal Rings Releasing Tenofovir with and without Levonorgestrel among Women in Western Kenya |
Principal Investigator(s) 1. DR. NELLY RWAMBA MUGO Site(s) in Kenya KEMRI CRC |
View |
302. |
ECCT/18/06/04 | RANDOMIZED CONTROLLED TRIAL OF STEPPED UP VITAMIN A SUPPLEMENTATION DOSE ON IMMUNE RESPONSES AMONG INFANTS 6-12 MONTHS AT BUSIA LEVEL 4 HOSPITAL IN BUSIA COUNTY, KENYA BUSIA LEVEL IV HOSPITAL |
Principal Investigator(s) 1. BENARD OCHIENG WESONGA Site(s) in Kenya Busia Level IV Hospital |
View |
303. |
ECCT/18/07/03 | Development of innovative integrated system to reduce malaria transmission towards elimination in the Lake Victoria basin, Kenya Development of innovative integrated system to reduce malaria transmission towards elimination in the Lake Victoria basin, Kenya |
Principal Investigator(s) 1. WATARU KAGAYA 2. KINYA UCHIHASHI Site(s) in Kenya HOMA BAY DISTRICT HOSPITAL |
View |
304. |
ECCT/18/07/07 | A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. GRACE KIRINGA KAGUTHI Site(s) in Kenya 1. Center for Respiratory Diseases Research (Siaya county) 2. KEMRI (Kisumu county) |
View |
305. |
ECCT/18/04/01 | CKAF156 STUDY A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria. |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. KEMRI CDC (Siaya county) 2. Walter Reed Project (Kisumu county) |
View |